What does “pediatric exclusivity” mean for FDA, and why years like 2020–2024 matter?
FDA pediatric exclusivity generally refers to the additional six months of market exclusivity granted under the Best Pharmaceuticals for Children Act (BPCA) and/or the Pediatric Research Equity Act (PREA) pathway when sponsors complete required pediatric studies. It affects the ability of other products to enter the market with generic/biosimilar products, because exclusivity can extend the approval “exclusivity clock” for certain drug products. [1]
Which FDA pediatric exclusivity grants were made in 2020, 2021, 2022, 2023, and 2024?
Your question asks for the specific FDA pediatric exclusivity grants by year (2020–2024). The provided information does not include a list of the products or the exact exclusivity grants for those years, so I can’t accurately name the granted exclusivities without the underlying FDA dataset or webpage you want used.
If you share a link (for example, the FDA “Pediatric Exclusivity” page you’re using, a specific FDA database/table, or a document listing the grants), I can extract and present the 2020–2024 product names and dates in a clean year-by-year format.
Where to look on FDA for the official year-by-year pediatric exclusivity list
FDA maintains the official reporting trail for pediatric exclusivity, typically via a dedicated pediatric exclusivity listing and supporting background pages that explain the program rules. [1]
Quick check: which program should your list come from (BPCA vs PREA)?
Depending on how your source defines “pediatric exclusivity,” the year-by-year entries might include different triggers:
- BPCA-related pediatric exclusivity (market exclusivity extension when pediatric studies are completed)
- PREA-related required pediatric studies (which can still link to exclusivity outcomes, but are not the same thing as “additional six months” in every context)
If you confirm which source/list you mean (BPCA pediatric exclusivity entries versus a broader “pediatric” dataset), I can align the answer to the right definition.
Send what you have, and I’ll produce the exact 2020–2024 list
Paste either:
- the FDA link you’re using, or
- the table rows/text for 2020–2024, or
- the names of the specific exclusivity entries you already found
…and I’ll return a year-by-year list (2020, 2021, 2022, 2023, 2024) with the product/drug name and the relevant exclusivity timing exactly as shown in your source.
Sources
- https://www.fda.gov/drugs/prescription-drug-advertisements/best-pharmaceuticals-children-act-and-pediatric-exclusivity